-
Product Insights
New![]()
Pied de Borne
Pied de Borne is a Hydro project located in Occitanie, France. The project is owned by Electricite de France SA. The project came online in 1965. Empower your strategies with our Pied de Borne report and make more profitable business decisions. Note: This is an on-demand report that will be delivered upon request. The report will be delivered within 2 to 3 business day of the purchase, excluding weekends and holidays. Certain sections of the report may be removed or...
-
Company Insights
New![]()
Innovation and Patenting activity of PI Industries Ltd Q3 2023
GlobalData, the industry analysis specialist, has released its latest company patent databook "Innovation and Patenting activity of PI Industries Ltd Q3 2023". The databook highlights patenting activity of the company in terms of growth in filings and grants, regions protected, impact of various themes, sector applicability of technologies protected. It provides contextual analysis of technical peers, their strategy, dominance (Grant share) and their recent activities. This is an on-demand databook that will be delivered upon request. The report will be...
-
Company Insights
New![]()
Innovation and Patenting activity of PI Advanced Materials Co Ltd Q3 2023
GlobalData, the industry analysis specialist, has released its latest company patent databook "Innovation and Patenting activity of PI Advanced Materials Co Ltd Q3 2023". The databook highlights patenting activity of the company in terms of growth in filings and grants, regions protected, impact of various themes, sector applicability of technologies protected. It provides contextual analysis of technical peers, their strategy, dominance (Grant share) and their recent activities. This is an on-demand databook that will be delivered upon request. The report...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Pi Kinase Inhibitor in Alzheimer’s Disease
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.Pi Kinase Inhibitor in Alzheimer's Disease Drug Details:The therapeutic candidate is under development for the treatment...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Alpha-1 Proteinase Inhibitor (Human) in Emphysema
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.Alpha-1 Proteinase Inhibitor (Human) in EmphysemaDrug Details:Alpha1-proteinase inhibitor human (Prolastin, Trypsone, Pulmolast, Lynspad) also known as...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Immune Globulin (Human) in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Immune Globulin (Human) in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Drug Details: Human Immunoglobulin (Gammabulin, Gammagard,...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Daratumumab in Myelodysplastic Syndrome
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Daratumumab in Myelodysplastic Syndrome Drug Details: Daratumumab ((HuMax-CD38, JNJ-54767414, Darzalex, Dalinvi) is an immunoglobulin...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Daratumumab in Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma)
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Daratumumab in Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma) Drug Details: Daratumumab ((HuMax-CD38, JNJ-54767414, Darzalex, Dalinvi) is...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Daratumumab in Triple-Negative Breast Cancer (TNBC)
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Daratumumab in Triple-Negative Breast Cancer (TNBC) Drug Details: Daratumumab ((HuMax-CD38, JNJ-54767414, Darzalex, Dalinvi) is...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Daratumumab in Refractory Acute Myeloid Leukemia
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Daratumumab in Refractory Acute Myeloid Leukemia Drug Details: Daratumumab ((HuMax-CD38, JNJ-54767414, Darzalex, Dalinvi) is...
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.